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Screening in Medullary Thyroid Carcinoma 
C. Calmettes* 
The four-year experience ofthe French collaborative study on medullary thyroid carcinoma (MTC) 
has permitted improvement in family screening by a common discussion of data and a network of 
coordinators throughout France involved in the detection of new cases. Investigations have been 
directed at improving the discrimination between sporadic and hereditary forms of MTC and between 
individuals who have or have not inherited the disease within families. (Henry Ford Hosp MedJ 
1987:35:99-100) 
Most clinicians lack experience in handling cases of medul-lary thyroid carcinoma (MTC); these tumors are not only 
rare but also difficult to manage. The French medullary thyroid 
study group was created in 1982 to collaboratively support re-
search on the disease and to help physicians caring for patients 
with MTC. A common protocol was established for patient man-
agement and for screening within families. Specialized study 
groups, a central registry of cases, and a network of regional 
coordinators were created to collect and analyze data. 
Tools for Screening 
The first objective of the group was to test the various tools for 
MTC screening. Since the diagnosis depends on calcitonin (CT) 
assay (1) and/or pathological examination, the efficacy ofthese 
techniques was analyzed and the network of coordinators was 
organized to study family members throughout France. 
CT assay 
A comparison of the different assay methods used in France 
confirmed and provided several conclusions: 
1. Artifacts can be excluded by means of serial dilutions ofthe 
plasma and the use of pentagastrin-stimulated CT test, which 
also allows discrimination between elevations of CT of thyroid 
or of ectopic origin (2). 
2. Any technique provides good results when the basal CT 
level is high, but variations in normal values obtained by 
different assays must be appreciated (3), and at times it is use-
ful to have duplicate aliquots assayed in different immuno-
assay systems. 
3. The pentagastrin-stimulated CT test is efficient in early de-
tection of MTC, but the upper limits of normal must be known 
for the particular assay used. This provocative test must be per-
formed in all cases of family screening, though an upper age 
limit needs to be determined [MTC can be still very small even 
after age 60 (4), as also observed in cases of our group]. This 
procedure also eliminates artifacts found in using basal CT 
levels only (5). 
Pathology 
Realizing the benefits of CT and thyroglobulin (Tg) immu-
nopathological studies in the diagnosis of the type of thyroid 
cancer (6), these studies were performed in specialized laborato-
ries. The use of these techniques allowed confirmation of the 
diagnosis of MTC and an estimation of C-cell hyperplasia. Inter-
estingly, this allowed recognition of atypical MTC, especially 
those with a trabecular, follicular (7), or papillary pattem, or Tg-
secreting carcinoma with amyloidosis mimicking MTC. 
Research on Criteria for Diagnosing Hereditary 
Forms of MTC 
Efforts of the group have been directed toward determining 
the criteria by which the hereditary form of MTC can be differ-
entiated from the sporadic form. If screening efforts can be con-
centrated to the families of those with the hereditary disease, 
much effort of screening can be saved and the costs decreased. 
Family screening 
Clinical screening may not always discriminate between the 
hereditary and sporadic forms of MTC because of unknown par-
entage, a limited number of available relatives, lack of family 
cooperation, and lack of knowledge of the type of cancer or thy-
roid disease in family members. 
Utilizing CT assay within families has limitations since it is 
not always possible to test enough family members to establish 
whether or not the disease is hereditary or sporadic. 
Pathology 
In our collaborative study, over 190 MTC cases have been 
collected, with most cases reviewed by ten histopathologists 
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(8). Cancers and/or C-cell hyperplasia are bilateral in hereditary 
MTC but also may occur, in our experience, in the sporadic 
form. Preliminary results suggest that a cancer limited to only 
one lobe of the thyroid gland without evident C-cell hyperplasia 
is a feature of the sporadic form only if adequate sections of the 
thyroid are available for study. 
The evolution of MTC is quite variable in both the sporadic 
and hereditary form. Even though the prognosis generally 
appears better in the hereditary form, the tumors are very 
aggressive in some of these cases. 
Endocrinology 
Studies have been carried out for ACTH, P-lipotropin, en-
dorphin, somatostatin (9-11), and CT-gene-related-peptide in 
plasma and in tumors. The increase in plasma of P-lipotropin 
seems to be more frequent in the hereditary form and of 
somatostatin in the sporadic form. 
HLA determination 
No linkage was observed between MTC and HLA type in sev-
eral families as presented in Cambridge by Guillausseau et al 
(12) and as reported by Simpson and Falk (13). 
Meta-iodo-benzylguanidine (MIBG) scintigraphy 
The results of the study of more than 50 cases have led 
Baulieu et al (14) to conclude that MIBG uptake in MTC is usu-
ally a feature of hereditary MTC. 
In summary, no technique has yet been able to discriminate 
between the hereditary and the sporadic form of MTC in all 
cases. Unfortunately, repetitive screening of family members 
remains necessary despite its difficulties. 
Results of Screening for MTC in France 
Although the registry was established in 1970, the common 
protocol was established only four years ago. The registry 
includes nearly 1,000 cases, with a high likelihood that 175 
cases are sporadic cases (based on extensive family screening 
and pathological criteria) and with 206 cases hereditary in 59 
families. In the past two years, one-half of the new cases have 
been hereditary. 
The hereditary cases appear to be isolated MTC in 29 families 
without other components of MEN-2 syndromes, MEN-2A in 
26 families and a few cases of the MEN-2B phenotype. The 
gene has a variable expression in MEN-2 even within the same 
family, with pheochromocytomas in 40% to 45% and para-
thyroid tumors in 16% to 18% of cases at the time of screening. 
The origin from the west of France (16 families) or Mediterra-
nean area (13 families, eight of which are foreign) should make 
interesting genealogic studies. The registry has permitted cases 
to be linked from different family branches. 
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